Advancing Personalized Cancer Vaccines Through AI-Driven Antigen Prediction & Clinical Translation
Time: 12:30 pm
day: Conference Day One
Details:
• How NEC Bio’s AI models improve the precision and relevance of neoantigen prediction, driving stronger immune responses and measurable patient benefit
• Integrating immunogenicity data and clinical outcomes to continuously refine AI models and improve predictive performance
• Insights from NECVAX-NEO1, a bacteria-based oral PCV, in improving delivery, accessibility, and patient experience beyond injectable formats
